Aligos Therapeutics
Capsid modulators have failed before. The graveyard is full of promising molecules that couldn't escape resistance or deliver antigen reductions. So what makes Aligos think they've solved it?
Aligos Therapeutics
The HBV cure race isn't winner-takes-all. It's a puzzle where multiple pieces need to fit together. Aligos positioned itself at the center of every solution - but the validation picture is murkier than it first appears.
Aligos Therapeutics
When the market prices your company below its cash balance, two things are true: either you're about to zero, or someone made a terrible mistake. At Aligos, the next 18 months will determine which.
Cognition Therapeutics
When a company with FDA-aligned Phase 3 plans and a clean safety profile trades below the value of its NIH grants, something is mispriced.
Cognition Therapeutics
Cognition Therapeutics is attempting to succeed where giants have stumbled. After a dramatic clinical setback, a key discovery has given its lead drug a new, targeted path forward in the world's most challenging disease.
Cognition Therapeutics
While Cognition Therapeutics' path in Alzheimer's has been redefined, the true long-term value of CT1812 may lie in its potential across a range of neurodegenerative diseases. From Dementia with Lewy Bodies to being a foundational therapy for all AD patients, the drug is far from a one-trick pony.
Cognition Therapeutics
With a clear regulatory path and a drug demonstrating broad potential, Cognition Therapeutics has the scientific assets. Now, it all comes down to the money. The company's future hinges on securing a strategic partnership, presenting investors with a classic high-risk, high-reward scenario.